Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection

被引:0
|
作者
Klim, Sebastian M. [1 ]
Prattes, Juergen [2 ]
Amerstorfer, Florian [1 ]
Niedrist, Tobias [3 ]
Zurl, Christoph [2 ]
Stradner, Martin [4 ]
Dreo, Barbara [4 ]
Glehr, Gunther [5 ]
Leithner, Andreas [1 ]
Glehr, Mathias [1 ]
Reinbacher, Patrick [1 ]
Sadoghi, Patrick [1 ]
Hauer, Georg [1 ]
机构
[1] Med Univ Graz, Dept Orthopaed & Trauma, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Internal Med, Div Infect Dis, A-8036 Graz, Austria
[3] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria
[4] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, A-8036 Graz, Austria
[5] Univ Hosp Regensburg, Dept Surg, D-93053 Regensburg, Germany
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 02期
关键词
suPAR; joint infection; synovia; inflammation; diagnostic biomarker; PLASMA; INFLAMMATION; ARTHRITIS; BIOMARKER; SEPSIS; LEVEL;
D O I
10.3390/antibiotics13020179
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Soluble urokinase plasminogen activator receptors (suPARs) are a biomarker for inflammatory diseases. This study aims to investigate its diagnostic properties regarding periprosthetic joint infections (PJI). This retrospective cohort study included adult patients who underwent joint puncture for suspected PJI. The presence of PJI was determined according to the criteria of the European Bone and Joint Infection Society (EBJIS). Laboratory study analyses included the determination of white blood cells (WBC) in whole blood, C-reactive protein (CRP) in blood plasma, and suPAR in both blood plasma and synovial fluid. Appropriate diagnostic cut-off values were identified utilizing Youden's J, and their diagnostic performance was determined by calculating the positive (PPV) and negative predictive value (NPV) for each marker. Sixty-seven cases were included in the final analysis. Forty-three samples (64%) were identified as periprosthetic joint infection (PJI) and twenty-four specimen (36%) were PJI negative cases. The PPV and NPV were 0.80 and 0.70 for synovial suPAR, 0.86 and 0.55 for CRP, 0.84 and 0.31 for WBC and 1.00 and 0.31 for plasma suPAR. Synovial suPAR showed a solid diagnostic performance in this study and has the potential to be an alternative or complementary biomarker for PJI. Further investigations in larger patient collectives are indicated.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Soluble urokinase-type plasminogen activator receptor is associated with signs of periodontitis in adolescents
    Skottrup, Peter D.
    Dahlen, Gunnar
    Baelum, Vibeke
    Lopez, Rodrigo
    EUROPEAN JOURNAL OF ORAL SCIENCES, 2018, 126 (04) : 292 - 299
  • [42] The relationship between levels of plasma-soluble urokinase plasminogen activator receptor (suPAR) and presence of migraine attack and aura
    Yilmaz, Nigar
    Yilmaz, Mustafa
    Sirin, Burcu
    Yilmaztekin, Sureyya
    Kutlu, Gulnihal
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2017, 37 (05) : 447 - 452
  • [43] The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Context of Aneurysmal Subarachnoid Hemorrhage (aSAH)-A Prospective Observational Study
    Schmidt, Tobias P.
    Albanna, Walid
    Weiss, Miriam
    Veldeman, Michael
    Conzen, Catharina
    Nikoubashman, Omid
    Blume, Christian
    Kluger, Daniel S.
    Clusmann, Hans
    Loosen, Sven H.
    Schubert, Gerrit A.
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [44] Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19
    Enocsson, Helena
    Idoff, Cornelia
    Gustafsson, Annette
    Govender, Melissa
    Hopkins, Francis
    Larsson, Marie
    Nilsdotter-Augustinsson, Asa
    Sjowall, Johanna
    FRONTIERS IN MEDICINE, 2021, 8
  • [45] Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism
    Engstrom, Gunnar
    Zoller, Bengt
    Svensson, Peter J.
    Melander, Olle
    Persson, Margaretha
    THROMBOSIS AND HAEMOSTASIS, 2016, 115 (03) : 657 - 662
  • [46] Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population
    Eugen-Olsen, J.
    Andersen, O.
    Linneberg, A.
    Ladelund, S.
    Hansen, T. W.
    Langkilde, A.
    Petersen, J.
    Pielak, T.
    Moller, L. N.
    Jeppesen, J.
    Lyngbaek, S.
    Fenger, M.
    Olsen, M. H.
    Hildebrandt, P. R.
    Borch-Johnsen, K.
    Jorgensen, T.
    Haugaard, S. B.
    JOURNAL OF INTERNAL MEDICINE, 2010, 268 (03) : 296 - 308
  • [47] Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
    Haastrup, Eva
    Grau, Katrine
    Eugen-Olsen, Jesper
    Thorball, Christian
    Kessing, Lars Vedel
    Ullum, Henrik
    PLOS ONE, 2014, 9 (10):
  • [48] The Role of Serum Soluble Urokinase-Type Plasminogen Activator Receptor in Stable Chronic Obstructive Pulmonary Disease
    Can, Ummugulsum
    Guzelant, Asuman
    Yerlikaya, Fatma Humeyra
    Yosunkaya, Sebnem
    JOURNAL OF INVESTIGATIVE MEDICINE, 2014, 62 (07) : 938 - 943
  • [49] Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults
    Olson, Nels C.
    Raffield, Laura M.
    Moxley, Anne H.
    Miller-Fleming, Tyne W.
    Auer, Paul L.
    Franceschini, Nora
    Ngo, Debby
    Thornton, Timothy A.
    Lange, Ethan M.
    Li, Yun
    Nickerson, Deborah A.
    Zakai, Neil A.
    Gerszten, Robert E.
    Cox, Nancy J.
    Correa, Adolfo
    Mohlke, Karen L.
    Reiner, Alexander P.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2021, 14 (06): : 740 - 748
  • [50] Association of plasma soluble urokinase plasminogen activator receptor concentrations and migraine with aura: a REFORM study
    Tesfay, Betel
    Ashina, Hakan
    Christensen, Rune Haeckert
    Al-Khazali, Haidar M.
    Karlsson, William Kristian
    Amin, Faisal Mohammad
    Jawad, Baker Nawfal
    Andersen, Ove
    Ashina, Messoud
    BRAIN COMMUNICATIONS, 2025, 7 (01)